GC Wealth Management RIA LLC Sells 2,646 Shares of Pfizer Inc. (NYSE:PFE)

GC Wealth Management RIA LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 12.0% during the 4th quarter, Holdings Channel reports. The fund owned 19,356 shares of the biopharmaceutical company’s stock after selling 2,646 shares during the quarter. GC Wealth Management RIA LLC’s holdings in Pfizer were worth $514,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Donaldson Capital Management LLC boosted its stake in Pfizer by 1.2% during the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock worth $947,000 after acquiring an additional 410 shares during the last quarter. Staley Capital Advisers Inc. boosted its stake in Pfizer by 3.5% during the 4th quarter. Staley Capital Advisers Inc. now owns 2,150,418 shares of the biopharmaceutical company’s stock worth $57,051,000 after acquiring an additional 73,594 shares during the last quarter. Miller Financial Services LLC bought a new position in Pfizer during the 4th quarter worth approximately $431,000. King Luther Capital Management Corp boosted its stake in Pfizer by 1.4% during the 4th quarter. King Luther Capital Management Corp now owns 2,535,085 shares of the biopharmaceutical company’s stock worth $67,256,000 after acquiring an additional 34,070 shares during the last quarter. Finally, Citizens Financial Group Inc. RI lifted its stake in Pfizer by 9.9% in the fourth quarter. Citizens Financial Group Inc. RI now owns 334,663 shares of the biopharmaceutical company’s stock valued at $8,879,000 after buying an additional 30,186 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on PFE. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Guggenheim reaffirmed a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Down 2.4 %

Shares of NYSE:PFE opened at $26.00 on Wednesday. The company’s 50-day moving average price is $26.29 and its two-hundred day moving average price is $27.19. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a market capitalization of $147.33 billion, a PE ratio of 18.44, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.62%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend was Friday, January 24th. Pfizer’s dividend payout ratio is presently 121.99%.

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.